Sublingual edaravone–dexborneol for chemo-related cognitive problems.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 4, single-site interventional trial administers a sublingual combination of edaravone and dexborneol to patients who develop chemotherapy-induced cognitive impairment while receiving single-agent chemotherapy. Participants are adults aged 35–80 with histologically confirmed non‑CNS malignancies who can complete cognitive questionnaires in Chinese and provide biopsy results. The protocol excludes people on concurrent therapeutic drugs or with central nervous system tumors and requires written informed consent. Outcomes focus on changes in attention, memory, and executive function over the treatment period to see if the medication improves everyday thinking and functioning.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Patients receiving \*\*monotherapy with any chemotherapeutic agent\*\* (including but not limited to):
* \*Alkylating agents\*: Cyclophosphamide, Carmustine, Lomustine, Temozolomide, etc.
* \*Antimetabolites\*: 5-Fluorouracil, Methotrexate, Capecitabine, Gemcitabine, etc.
* \*Platinum-based drugs\*: Cisplatin, Carboplatin, Oxaliplatin, etc.
* \*Taxanes\*: Paclitaxel, Docetaxel, etc.
* \*Anthracyclines\*: Doxorubicin, Epirubicin, etc.
* \*Other agents\*: Vincristine, Etoposide, Irinotecan, etc.

  * and\*\* meeting all subconditions\*\*:
* No concurrent use of other therapeutic drugs
* Histologically confirmed malignant tumor (excluding central nervous system tumors) requiring chemotherapy
* Availability of tissue biopsy results

  2\. Full comprehension of the study's purpose, potential adverse reactions, and provision of \*\*written informed consent\*\*.

  3\. Aged \*\*35-80 years\*\*, fluent in Chinese, cognitively capable of completing questionnaires independently, \*\*with caregiver assistance\*\* for questionnaire completion.

  4\. Initial complaint of cognitive impairment (memory and/or other domains) \*\*occurring ≥3 months before chemotherapy initiation\*\*.

  5\. Completion of cancer treatment with \*\*curative intent\*\* (excluding post-chemotherapy endocrine therapy).

  6\. \*\*Clinical Dementia Rating (CDR)\*\* global score of \*\*0.5-2\*\* (indicating questionable to moderate cognitive impairment) and \*\*no significant visual or auditory deficits

Exclusion Criteria:

* 1\. Established diagnosis of \*\*cognitive impairment disorders\*\* (e.g., Alzheimer's disease, frontotemporal dementia, Parkinson's dementia).

  2\. Primary or metastatic \*\*central nervous system malignancies\*\*. 3. History of \*\*brain metastases or other intracranial tumors\*\*. 4. Severe \*\*head trauma\*\* or stroke with significant residual deficits (\*\*Activities of Daily Living \[ADL\] score \< 60\*\*).

  5\. Poorly controlled \*\*epilepsy\*\* or other seizure disorders. 6. \*\*Contraindications to MRI\*\* (e.g., claustrophobia, cardiac pacemakers, metal implants) - \*excluded from fMRI testing only\*; otherwise eligible participants may enroll without fMRI.

  7\. Current use of \*\*cognition-affecting medications\*\*, including but not limited to:
* \*Cholinesterase inhibitors\*: Donepezil, Rivastigmine, Galantamine
* \*NMDA receptor antagonists\*: Memantine
* \*Other agents\*: Sodium oligomannate, Ginkgo biloba extract, Oxiracetam, Piracetam, Nicergoline, Lecanemab, Aducanumab 8. \*\*Pregnancy\*\*, lactation, or plans for pregnancy. 9. Active \*\*neurological or untreated/unremitted psychiatric disorders\*\* (e.g., active major depressive disorder per DSM-5; \*stable treated depression permitted\*).

  10\. \*\*Alcohol/substance abuse or dependence\*\* within the past 2 years. 11. \*\*Clinically significant systemic diseases/unstable medical conditions\*\*, including:
* Cardiac: Myocardial infarction (≤1 year), unstable angina, congestive heart failure, or clinically abnormal ECG
* Pulmonary: Acute asthma exacerbation, pulmonary embolism
* Gastrointestinal: Active bleeding, inflammatory bowel disease
* Hepatic: Cirrhosis or ALT/AST \>2× ULN
* Renal: Serum creatinine \>1.5× ULN 12. Use of \*\*non-study cognition-enhancing drugs\*\* within 4 weeks prior to enrollment.

  13\. Use of edaravone dexborneol within 30 days prior to enrollment.

Where it's running

• The First Affiliated Hospital of China Medical University
  Shenyang, Liaoning, China Recruiting

Study contacts

• Study coordinator: chuansheng zhao
• Email: cszhao@cmu.edu.cn
• Phone: +86-13940369251

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Platinum chemotherapy and hearing in cancer patients from deprived communities

  This study tests how platinum-based chemotherapy affects hearing in cancer patients living in the North West of England and whether socioeconomic deprivation influences risk.

  Recruiting Lancaster University · Lancaster, Lancashire · NCT07553481

• Using a smartphone brain-training app to reduce chemo‑brain in gynecologic cancer patients

  This will test whether a mobile cognitive training app can reduce chemo‑brain symptoms in people with gynecologic cancers who are receiving chemotherapy.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama · NCT05864274

• Investigating cognitive impairment in young cancer patients during and after chemotherapy

  This study is testing how chemotherapy affects memory and attention in children and young adults with cancer to better understand their cognitive challenges during and after treatment.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Copenhagen · NCT05840575

• Exploring cognitive impairment in breast cancer patients

  This study is trying to see if certain brain changes in young women with breast cancer who are undergoing chemotherapy and hormone therapy can help predict memory and thinking problems, so doctors can choose better treatment plans.

  Recruiting Tang-Du Hospital · Xi'an, Shaanxi · NCT05305092

• Examining brain changes in colorectal cancer patients undergoing chemotherapy

  This study is trying to see how chemotherapy affects thinking and memory in people with colorectal cancer.

  Recruiting Parkview Health · Fort Wayne, Indiana · NCT05014399

• Effects of chemotherapy on cognition and brain changes in older breast cancer patients

  This study tests how chemotherapy affects thinking and memory in older breast cancer patients compared to healthy volunteers.

  Recruiting at 2 sites Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT02290834

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.